ITGB7: Integrin beta-7
Integrin ITGA4/ITGB7 (alpha-4/beta-7) (Peyer patches-specific homing receptor LPAM-1) is an adhesion molecule that mediates lymphocyte migration and homing to gut-associated lymphoid tissue (GALT) (Probable).
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on ITGB7, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Etrolizumab | Phase 3 | Roche | Antibody | AntagonistIntegrin beta-7 antagonist | 0 |
- Ulcerative colitis0.60
- Crohn disease0.60
- Inflammation0.37
- Mathematical ability0.31
- Inflammatory bowel disease0.27
- Sclerosing cholangitis0.26
- Pouchitis0.26
- Colitis0.11
- HIV infectious disease0.10
- Acute graft versus host disease0.10
- Miyoshi myopathy0.10
- Ischemic stroke0.09
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2979, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P26010, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets